Danaher (NYSE:DHR) Sets New 1-Year Low After Analyst Downgrade

Danaher Co. (NYSE:DHRGet Free Report) reached a new 52-week low during trading on Thursday after Jefferies Financial Group lowered their price target on the stock from $285.00 to $260.00. Jefferies Financial Group currently has a buy rating on the stock. Danaher traded as low as $223.00 and last traded at $223.12, with a volume of 11405161 shares traded. The stock had previously closed at $247.84.

Other analysts also recently issued research reports about the stock. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price on the stock in a research report on Thursday, October 31st. Citigroup dropped their target price on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. JPMorgan Chase & Co. dropped their target price on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research report on Tuesday. Evercore ISI boosted their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Six equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and a consensus target price of $284.14.

Get Our Latest Stock Analysis on Danaher

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Heck Capital Advisors LLC acquired a new position in shares of Danaher in the 4th quarter valued at $27,000. Decker Retirement Planning Inc. acquired a new position in shares of Danaher in the 4th quarter valued at $31,000. Golden State Wealth Management LLC acquired a new position in shares of Danaher in the 4th quarter valued at $31,000. Strategic Financial Concepts LLC purchased a new position in Danaher in the 4th quarter valued at $31,000. Finally, Pineridge Advisors LLC grew its position in Danaher by 63.3% in the 4th quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after buying an additional 57 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 10.0 %

The business’s 50-day moving average is $236.09 and its two-hundred day moving average is $253.66. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The stock has a market capitalization of $161.15 billion, a PE ratio of 42.58, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHRGet Free Report) last posted its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. During the same period last year, the business posted $2.09 EPS. As a group, equities research analysts anticipate that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.48%. Danaher’s payout ratio is currently 20.61%.

About Danaher

(Get Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

See Also

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.